Thursday, May 06, 2021

Panama approves emergency use of Chinese CoronaVac vaccine

Panama approves emergency use of Chinese CoronaVac vaccine

Panama's health authorities approved this Friday the emergency use of the CoronaVac, from the Chinese pharmaceutical company Sinovac.
Elvia Lau, national director of the department of pharmacies and drugs, indicated that the approval of this inactive COVID-19 Vero cell vaccine is carried out after evaluating several factors, such as compliance with good manufacturing practices.

"We check if the manufacturing laboratory complies with good manufacturing practices, which is the main thing, which gives us a guarantee that this product is of quality, the inclusion and exclusion parameters of this vaccine and everything else are also verified. what is the pharmacovigilance plan; all the adverse reactions that have occurred with the vaccine in its experimental phase and we also see the risk management plan”, said Lau.

The Ministry of Health (Minsa) reported that each vial of the CoronaVac vaccine represents one person, must be applied twice with an interval of up to four weeks, and must be kept at a temperature of 2 to 8 degrees Celsius for transport and storage.

"It is one more opportunity for Panamanians to have another vaccine here in the country and that more people can be immunized, and achieve herd immunity at some point," Lau stressed.

It is worth mentioning that the Minsa announced on April 3 that the Pharmacies and Drugs Directorate had begun the process of reviewing the folder of the Chinese CoronaVac vaccine from the pharmaceutical company Sinovac against COVID-19.

She indicated that it is the vaccine with series 004-DNFD and becoming the fourth vaccine with authorization for emergency use in the country.

Currently in the country the vaccine developed by the American pharmaceutical company Pfizer is being applied, and last week the Pharmacies and Drugs authorized the emergency use of the Russian Sputnik V vaccine, after concluding with the reviews of the dossier.

Related Articles